Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Baker Medical Research Institute, Australia
Researchers from Australia and the United States provide details of new studies and findings in the area of diabetes
August 18th, 2006
New findings from Australia and the United States describe advances in diabetes. Study 1: Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin alpha) Therapy (TREAT) is expected to find the optimal approach to the management of anemia in diabetes. "Anemia is a common finding in patients with diabetes, particularly in those with overt nephropathy or renal impairment. In tertiary clinics, at least one outpatient in five with diabetes has anemia, for whom it constitutes a significant additional burden," scientists writing in the journal Diabetologia report in their discussion. M.C. Thomas and colleagues at Baker...
Source: Biotech Law Weekly (2006-08-18)
|
